Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's

Inclusion Criteria: * Histological proven diagnosis of Lymphoplasmacytic/cytoid lymphoma/Waldenstrom macroglobulinemia according to REAL/WHO Classification * Relapsed/refractory disease after receiving one line chemotherapy (rituximab). If patients received bortezomib or bendamustine and have obtained a partial response lasting at least two years. * Age \>= 18 * Presence of at least one of the following criteria for the definition of active disease: Systemic symptoms or Hemoglobin less than 10 g/dL (due to lymphoma) or Platelets less than 100 x 109/L (due to lymphoma) or symptomatic splenomegaly or Bulky disease (\>7 cm) or Hyperviscosity syndrome, peripheral neuropathy up to grade 1 (Waldenstrom's disease-related), hemolytic anemia, and immune complex vasculitis * Life expectancy \>6 months * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * left ventricular ejection fraction (LVEF) ≥45% or FS ≥37% * Creatinine up to 1.5 x upper limit of normal * Conjugated bilirubin up to 2 x upper limit of normal * Alkaline phosphatase and transaminases up to 2 x upper limit of normal * Written informed content Exclusion Criteria: * Patients who received bortezomib or bendamustine first-line therapy, that or haven't obtained at least partial response nor partial response lasting at least two years. * Patients not agreeing to take adequate contraceptive precautions during and for at least 6 months after cessation of therapy * History of other malignancies within 3 years prior to study entry except for: adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage, localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent * Medical condition requiring long term use (\>1 months) of systemic corticosteroids * Active bacterial, viral, or fungal infection requiring systemic therapy * Peripheral neuropathy of any grade ≥ 2 \[see Appendix Section A\] * Concurrent medical condition which might exclude administration of therapy * Cardiac insufficiency (NYHA grade III/IV) * Myocardial infarction within 6 months of entry on study * Severe chronic obstructive pulmonary disease with hypoxemia * Severe diabetes mellitus difficult to control with adequate insulin therapy * Hypertension that is difficult to control * Impaired renal function with creatinine clearance \<30 ml/min * HIV positivity HBV positivity with the exception of patients HbsAg and HBV-DNA negative and Ab anti-HB core positive (these patients need to receive prophylaxis with Lamivudine) * HCV positivity with the exception of patients with HCV RNA negative * Participation at the same time in another study in with investigational drugs are used * Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins * Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent. * Women in pregnancy or breastfeeding